Cohance Lifesciences Limited has informed the Exchange about change in Management
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences has announced a leadership change at its CDMO (Contract Development and Manufacturing) business. Dr. Sudhir Kumar Singh, the current CEO overseeing the CDMO business, has resigned citing health issues and will step down from close of business on July 31, 2025. He will, however, stay on under his existing contract to help with a smooth transition. To fill the role, the company has appointed Mr. Yann D'Herve as the new CEO – CDMO Business, effective August 1, 2025. Yann joins from Evonik, where he most recently served as Senior Vice President and General Manager of the Healthcare division, managing 2,600 employees across 9 manufacturing sites. The change was approved by the Board via circular resolution based on the Nomination and Remuneration Committee's recommendation.
The change is a like-for-like replacement of the CDMO business head, with an experienced external hire from a global major (Evonik), which should reassure investors. The outgoing CEO's health-related exit appears orderly with a planned handover, reducing execution risk. Near-term stock impact is likely neutral, though the new appointee's global experience could be viewed positively for the CDMO growth strategy.